Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Recurrence 5Lymphoma, Non-Hodgkin 3Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

10-propargyl-10-deazaaminopterin 6Brentuximab Vedotin 5romidepsin 3Vitamin B 12 3Rituximab 3Folic Acid 3Cyclophosphamide 3tenalisib 2cobomarsen 2belinostat 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2zanubrutinib 1zanolimumab 1venetoclax 1tislelizumab 1quisinostat 1pembrolizumab 1mogamulizumab 1fostamatinib 1forodesine 1fludarabine 1enzastaurin 1enzalutamide 1duvelisib 1denileukin diftitox 1darinaparsin 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell × Alemtuzumab × Clear all
NCT05557903 2022-09-28

Phase â…  Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lanzhou Institute of Biological Products Co., Ltd

Phase 1 Unknown
71 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡